TScan Therapeutics, Inc.TCRXNASDAQ
Loading
R&D Expenses Over TimeStrong
Percentile Rank100
3Y CAGR+23.8%
5Y CAGR+40.7%
Studio
Year-over-Year Change

Research and development spending

3Y CAGR
+23.8%/yr
Annual compound
5Y CAGR
+40.7%/yr
Recent deceleration
Percentile
P100
Near historical high
vs 5Y Ago
5.5x
Strong expansion
Streak
6 yr
Consecutive growthStrong
PeriodValueYoY Change
TTM$113.56M+5.8%
2024$107.35M+21.8%
2023$88.15M+47.4%
2022$59.82M+33.1%
2021$44.95M+118.5%
2020$20.58M+117.9%
2019$9.44M-